# Elanco Animal Health corporate activity

> Live situation record from CLSTR: https://clstr.news/situations/elanco-animal-health-corporate-activity
> Updated: 2026-08-06T08:21:00.000Z. Sources: 5. Developments: 2.

In early August 2026, institutional investors increased their holdings in Elanco Animal Health, with Defilade Capital Management boosting its stake by 132% to about 0.19% of the company. Several other firms also raised their positions, lifting overall institutional ownership to roughly 97.5%. Around the same time, CEO Jeffrey N. Simmons purchased nearly 5,000 shares, bringing his personal stake to about $3.45 million.

A few days later, Elanco announced an upward revision of its 2026 revenue outlook, now forecasting $5.09‑$5.14 billion and a higher innovation‑revenue target. The company cited a 12% year‑over‑year rise in pet‑health revenue, driven by increased demand for tick‑preventive treatments and a new dermatology product gaining significant market share in Europe. The earnings lift was mirrored by strong results across the broader animal‑health sector.

## Timeline

### 2026-08-06: Elanco Animal Health lifts earnings outlook on surge in tick‑related demand

Elanco Animal Health raised its 2026 revenue outlook to $5.09‑$5.14 billion, citing a tick‑bite driven surge in preventive pet‑health demand; peers also reported resilient earnings.

3 sources. https://clstr.news/cluster/elanco-animal-health-lifts-earnings-outlook-on-surge-in-tickrelated-demand

### 2026-08-02: Elanco Animal Health draws sizable institutional investment and CEO share purchase

Defilade Capital boosted its Elanco stake to 0.19% and other institutions raised holdings, while CEO Jeffrey Simmons bought nearly 5,000 shares, lifting his ownership to $3.45 million.

2 sources. https://clstr.news/cluster/elanco-animal-health-draws-sizable-institutional-investment-and-ceo-share-purchase

---
Cite as: Elanco Animal Health corporate activity. CLSTR, https://clstr.news/situations/elanco-animal-health-corporate-activity